Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis.
Patrick R Lawler,Garen Manvelian, Alida Coppi,Amy Damask,Michael N Cantor,Manuel A R Ferreira,Charles Paulding,Nilanjana Banerjee,Dadong Li, Susan Jorgensen,Richa Attre,David J Carey,Kristi Krebs,Lili Milani,Kristian Hveem,Jan K Damås,Erik Solligård,Stefan Stender,Anne Tybjærg-Hansen,Børge G Nordestgaard,Tamara Hernandez-Beeftink,Tormod Rogne,Carlos Flores,Jesús Villar,Keith R Walley,Vincent X Liu,Alison E Fohner,Luca A Lotta,Christos A Kyratsous,Mark W Sleeman,Michel Scemama,Richard DelGizzi,Robert Pordy,Julie E Horowitz,Aris Baras,Greg S Martin,Philippe Gabriel Steg,Gregory G Schwartz,Michael Szarek,Shaun G Goodman Critical care explorations（2023）
摘要
PCSK9 inhibition may improve clinical outcomes in sepsis in preventive, pretreatment settings.
更多查看译文
关键词
proprotein convertase subtilisin/kexin,sepsis,subtilisin/kexin type,genetic downregulation
AI 理解论文
溯源树
样例
